Amendment - 2nd Reading-yellow - Requested by: Marta Bertoglio - (H) Committee of the
Whole
- 2025
69th Legislature 2025 Drafter: Jameson Walker, HB0740.002.001
1 HOUSE BILL NO. 740
2 INTRODUCED BY M. BERTOGLIO, M. THANE, Z. WIRTH
3
4 A BILL FOR AN ACT ENTITLED: “AN ACT GENERALLY REVISING LAWS RELATING TO PHARMACIES,
5 PHARMACY BENEFIT MANAGERS, AND OTHER ENTITIES; PROVIDING LAWS RELATING TO THE
6 RECOUPMENT OF FUNDS; PROVIDING DEFINITIONS; REVISING LAWS RELATED TO MAXIMUM
7 ALLOWABLE COST OR THE REFERENCE PRICE LIST; PROHIBITING CERTAIN FEES; EXEMPTING THE
8 GROUP HEALTH INSURANCE PLAN OF CERTAIN EMPLOYEES; AND AMENDING SECTIONS 33-2-2005,
9 33-22-170, 33-22-171, 33-22-172, 33-22-175, AND 33-22-177, AND 39-71-727, MCA; AND PROVIDING AN
10 APPLICABILITY SECTION.”
11
12 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MONTANA:
13
14 Section 1. Section 33-2-2005, MCA, is amended to read:
15 "33-2-2005. Prohibitions -- recoupment -- payment -- interest. An entity conducting an audit may
16 not:
17 (1) include dispensing fees unless a prescription was not actually dispensed, the prescriber denied
18 authorization, the prescription dispensed was a dispensing error by the pharmacy, or the identified
19 overpayment is based solely on an extra dispensing fee;
20 (2) recoup funds for prescription clerical or recordkeeping errors, including typographical errors,
21 scrivener's errors, and computer errors, in a required document or record unless the error results in actual
22 financial harm to the entity or to a consumer;
23 (3) collect any funds, charge-backs, or penalties until the audit and all appeals are final unless the
24 entity is alleging fraud or other intentional or willful misrepresentation that is evidenced by the review of claims
25 data, statements, physical review, or other investigative methods;
26 (4) use extrapolation or other statistical expansion techniques in calculating the amount of any
27 recoupment or penalty;
- 1 - Authorized Print Version – HB 740

Amendment - 2nd Reading-yellow - Requested by: Marta Bertoglio - (H) Committee of the
Whole
- 2025
69th Legislature 2025 Drafter: Jameson Walker, HB0740.002.001
1 (5) pay the agent or employee who conducted the audit based on a percentage of the amount
2 recovered; or
3 (6) charge interest during the audit period; or
4 (7) recoup funds on the basis of the timing of purchases of dispensed medication, but instead shall
5 permit a pharmacy to use drug purchase records without limitation of date or source to validate the dispensing
6 of legend or narcotic drugs so long as the purchase of the drug was done in accordance with state or federal
7 law."
8
9 Section 2. Section 33-22-170, MCA, is amended to read:
10 "33-22-170. Definitions. As used in 33-22-170 through 33-22-177 and 33-22-180, the following
11 definitions apply:
12 (1) "Contract pharmacy" means a pharmacy operating under contract with a federally certified
13 health entity to provide dispensing services to the federally certified health entity.
14 (2) "Effective rate contracting" means an agreement or arrangement between a pharmacy or a
15 contracting agent acting on behalf of a pharmacy and a pharmacy benefit manager or third-party payer that
16 establishes a reimbursement rate for pharmaceuticals based on the effective rate of payment rather than on a
17 predetermined fixed price or a fixed discount percentage.
18 (2) (3) "Federally certified health entity" means a 340B covered entity as described in 42 U.S.C.
19 256b(a)(4).
20 (3) (4) "Maximum allowable cost list" means the list of drugs used by a pharmacy benefit manager that
21 sets the maximum cost on which reimbursement to a network pharmacy or pharmacist is based.
22 (4) (5) "Pharmacist" means a person licensed by the state to engage in the practice of pharmacy
23 pursuant to Title 37, chapter 7.
24 (5) (6) "Pharmacy" means an established location, either physical or electronic, that is licensed by the
25 board of pharmacy pursuant to Title 37, chapter 7, and that has entered into a network contract with a
26 pharmacy benefit manager, health insurance issuer, or plan sponsor.
27 (6) (7) "Pharmacy benefit manager" means a person who contracts with pharmacies on behalf of a
- 2 - Authorized Print Version – HB 740

Amendment - 2nd Reading-yellow - Requested by: Marta Bertoglio - (H) Committee of the
Whole
- 2025
69th Legislature 2025 Drafter: Jameson Walker, HB0740.002.001
1 health insurance issuer, third-party administrator, or plan sponsor to process claims for prescription drugs,
2 provide retail network management for pharmacies or pharmacists, pay pharmacies or pharmacists for
3 prescription drugs, or provide other prescription drug or device services.
4 (7) (8) "Pharmacy performance measurement entity" means:
5 (a) the electronic quality improvement platform for plans and pharmacies; or
6 (b) an entity approved by the board of pharmacy provided for in 2-15-1733 as a nationally
7 recognized and unbiased entity that assists pharmacies in improving performance measures.
8 (8) (9) "Pharmacy services administrative organization" means an entity that acts as a contracting
9 agent or provides contracting and other administrative services to pharmacies to assist them in their
10 interactions with third-party payers and pharmacy benefit managers.
11 (9) (10) "Prescription drug" means any drug that is required by federal law or regulation to be
12 dispensed only by a prescription subject to section 353(b) of the Federal Food, Drug, and Cosmetic Act, 21
13 U.S.C. 301 et seq.
14 (10) (11) "Prescription drug order" has the meaning provided in 37-7-101.
15 (11) (12) "Reference pricing" means a calculation for the price of a pharmaceutical that uses the
16 most current nationally recognized reference price or amount to set the reimbursement for prescription drugs
17 and other products, supplies, and services covered by a network contract between a plan sponsor, health
18 insurance issuer, or pharmacy benefit manager and a pharmacy or pharmacist."
19
20 Section 3. Section 33-22-171, MCA, is amended to read:
21 "33-22-171. Maximum allowable cost list -- limitations on drugs. Before a pharmacy benefit
22 manager places or continues a drug on a maximum allowable cost list, the drug:
23 (1) must be listed as "A" or "B" rated in the most recent version of the United States food and drug
24 administration's approved drug products with therapeutic equivalence evaluations or have an "NR" or "NA"
25 rating by a nationally recognized reference;
26 (2) must be available for purchase by pharmacies in this state from national or regional
27 wholesalers; and
- 3 - Authorized Print Version – HB 740

Amendment - 2nd Reading-yellow - Requested by: Marta Bertoglio - (H) Committee of the
Whole
- 2025
69th Legislature 2025 Drafter: Jameson Walker, HB0740.002.001
1 (3) may not be obsolete, temporarily unavailable, or listed on a drug shortage list."
2
3 Section 4. Section 33-22-172, MCA, is amended to read:
4 "33-22-172. Maximum allowable cost or reference price list -- price formulation, updating, and
5 disclosure -- exceptions. (1) At the time of entering into a contract with a pharmacy or a pharmacy services
6 administrative organization and subsequently upon request, a plan sponsor, health insurance issuer, or
7 pharmacy benefit manager shall provide the pharmacy or pharmacy services administrative organization with
8 the sources used to determine the pricing for the maximum allowable cost list or the reference used for
9 reference pricing.
10 (2) If using a maximum allowable cost list, a plan sponsor, health insurance issuer, or pharmacy
11 benefit manager shall:
12 (a) review and update the price information for each drug on the maximum allowable cost list at
13 least once every 10 calendar days to reflect any modification of pricing, ensuring that maximum allowable cost
14 increases are processed and updated on the same schedule as decreases;
15 (b) establish a process for eliminating products from the maximum allowable cost list or modifying
16 the prices in the maximum allowable cost list in a timely manner to remain consistent with pricing changes and
17 product availability in the marketplace; and
18 (c) provide a process for each pharmacy to readily access the maximum allowable cost list specific
19 to the pharmacy in a searchable and usable format.
20 (3) If using reference pricing, a plan sponsor, health insurance issuer, or pharmacy benefit
21 manager shall:
22 (a) review and update no less than every 10 business days daily the price information for each
23 drug, product, supply, or service for which reference pricing is used, updating reference pricing on the same
24 date of the change in the referenced source; and
25 (b) provide a process for each pharmacy to readily access the reference pricing specific to the plan
26 sponsor or the health insurance issuer's plan.
27 (4) A plan sponsor, health insurance issuer, or pharmacy benefit manager may not:
- 4 - Authorized Print Version – HB 740

Amendment - 2nd Reading-yellow - Requested by: Marta Bertoglio - (H) Committee of the
Whole
- 2025
69th Legislature 2025 Drafter: Jameson Walker, HB0740.002.001
1 (a) prohibit a pharmacist from discussing reimbursement criteria with a covered person;
2 (b) penalize a pharmacy or a pharmacist for disclosing the information described in subsection
3 (4)(a) to a covered person or for selling a more affordable alternative to a covered person; or
4 (c) require a pharmacy to charge or collect a copayment from a covered person that exceeds the
5 total charges submitted by the network pharmacy.
6 (5) (a) A plan sponsor, pharmacy benefits manager, or third-party payer shall ensure that
7 reimbursement to pharmacies for each drug dispensed is no less than 106% of the national average drug
8 acquisition cost plus a professional dispensing fee that is no less than the fee-for-service rate employed by the
9 Montana department of public health and human services authority for the Medicaid program. The national
10 average drug acquisition cost price must be the price published in effect for the day the drug claim was billed by
11 the pharmacy.
12 (b) In the event that a particular drug does not have a published national average drug acquisition
13 price, the reimbursement must be:
14 (i) for generic drugs, 110% of published wholesale acquisition costs plus a professional fee of that
15 is no less than the fee-for-service rate employed by the Montana department of health and human services
16 authority for the Medicaid program; and
17 (ii) for brand-name drugs, 100% of wholesale acquisition costs plus a professional fee of that is no
18 less than the fee-for-service rate employed by the Montana department of health and human services authority
19 for the Medicaid program."
20
21 Section 5. Section 33-22-175, MCA, is amended to read:
22 "33-22-175. Allowable and prohibited fees on pharmacies. (1) A pharmacy benefit manager, or a
23 third-party payer, or a discount card processor may not directly or indirectly charge or hold a pharmacy
24 responsible for a fee, related to a claim including but not limited to the following:
25 (a) a fee for submission of a claim;
26 (b) any other claim-related fee;
27 (c) a fee for enrollment or participation in a retail pharmacy network;
- 5 - Authorized Print Version – HB 740

Amendment - 2nd Reading-yellow - Requested by: Marta Bertoglio - (H) Committee of the
Whole
- 2025
69th Legislature 2025 Drafter: Jameson Walker, HB0740.002.001
1 (d) a credentialing or recredentialing fee;
2 (e) a fee for the development or management of claims processing services or claims payment
3 services; or
4 (f) a fee on remittance advice or a fee that is retroactive if the fee is not apparent at the time the
5 claim is processed;
6 (b) if the fee is not reported on the remittance advice of an adjudicated claim; or
7 (c) after the initial claim is adjudicated.
8 (2) A pharmacy benefit manager or third-party payer may collect a performance-based fee from a
9 pharmacy only if the pharmacy fails to meet the criteria established by a pharmacy performance measurement
10 entity. The fee may be applied only to the professional dispensing fee outlined in the contract with the
11 pharmacy and may not be imposed on the cost of goods sold by a pharmacy.
12 (3) Only criteria established by a pharmacy performance measurement entity may be used to
13 measure a pharmacy's performance for the purposes of this section.
14 (4) A pharmacy benefits manager or third-party payer may not make or allow any reduction in
15 payment for pharmacy services by a pharmacy benefits manager or third-party payer or directly or indirectly
16 reduce a payment for a pharmacy service under a reconciliation process to an effective rate of reimbursement,
17 including generic effective rates, brand effective rates, direct and indirect remuneration fees, or any other
18 reduction or aggregate reduction of payments.
19 (5) All reimbursements to pharmacies must be made through direct bank transfers, checks, or
20 other payment methods that do not incur processing fees for the pharmacy. Checks must have a 180-day
21 expiration to deposit."
22
23 Section 6. Section 33-22-177, MCA, is amended to read:
24 "33-22-177. Rights of pharmacies. (1) A pharmacy benefit manager or third-party payer may not
25 prohibit a pharmacist or pharmacy from:
26 (a) participating in a class-action lawsuit;
27 (b) disclosing to the plan sponsor or to the patient information regarding the adjudicated
- 6 - Authorized Print Version – HB 740

Amendment - 2nd Reading-yellow - Requested by: Marta Bertoglio - (H) Committee of the
Whole
- 2025
69th Legislature 2025 Drafter: Jameson Walker, HB0740.002.001
1 reimbursement paid to the pharmacy if the pharmacist or pharmacy complies with the requirements of the
2 federal Health Insurance Portability and Accountability Act of 1996, 29 U.S.C. 1181 et seq.;
3 (c) providing relevant information to a patient about the patient's prescription drug order, including
4 but not limited to the cost and clinical efficacy of a more affordable alternative drug if one is available;
5 (d) mailing or delivering a prescription drug to a patient as an ancillary service of a pharmacy if the
6 practice is not prohibited under Title 37, chapter 7; or
7 (e) charging a shipping and handling fee to a patient who has asked that a prescription drug be
8 mailed or delivered if the practice is not prohibited under Title 37, chapter 7.
9 (2) A pharmacy benefit manager or third-party payer may not:
10 (a) require pharmacy accreditation standards or recertification requirements inconsistent with,
11 more stringent than, or in addition to federal and state requirements for licensure as a pharmacy in this state; or
12 (b) exclude a pharmacy from the pharmacy benefit manager's or third-party payer's network based
13 solely on the pharmacy being newly opened or open less than a defined amount of time, or because a license
14 or location transfer occurs, unless there is a pending investigation for fraud, waste, or abuse.
15 (3) A pharmacist or pharmacy that belongs to a pharmacy services administrative organization
16 may receive a copy of a contract the pharmacy services administrative organization entered into with a
17 pharmacy benefit manager or third-party payer on the pharmacy's or pharmacist's behalf.
18 (4) A pharmacy benefit manager or third-party payer shall provide a pharmacy or pharmacist with
19 the processor control number, bank identification number, and group number for each pharmacy network
20 established or administered by a pharmacy benefit manager or third-party payer to enable the pharmacy to
21 make an informed contracting decision.
22 (5) (a) A pharmacy benefit manager shall:
23 (i) offer a pharmacy or a pharmacy services administrative organization an opportunity to renew
24 an existing contract every 3 years, at a minimum; and
25 (ii) allow a pharmacy or a pharmacy services administrative organization to terminate a contract
26 upon a 90-day notice to the pharmacy benefit manager;
27 (iii) ensure pharmacy credentialing applications are processed and that pharmacies are added to
- 7 - Authorized Print Version – HB 740

Amendment - 2nd Reading-yellow - Requested by: Marta Bertoglio - (H) Committee of the
Whole
- 2025
69th Legislature 2025 Drafter: Jameson Walker, HB0740.002.001
1 applicable networks within 45 calendar days after all needed documentation has been submitted by the
2 pharmacy or the pharmacy services administrative organization.
3 (iv) ensure pharmacy ownership changes are processed and that the pharmacy can process
4 prescriptions for applicable networks within 30 calendar days after all needed documentation has been
5 submitted by the pharmacy or the pharmacy services administrative organization.
6 (b) An addendum or amendment to an existing contract between a pharmacy benefit manager and
7 a pharmacy or a pharmacy services administrative organization is effective only upon signing of the addendum
8 or amendment by both parties.
9 (6) A pharmacy or a pharmacy services administrative organization has a private right of action to
10 enforce provisions of 33-22-175 through 33-22-177.
11 (7) Effective rate contracting is prohibited in all agreements between pharmacies or contracting
12 agents acting on behalf of a pharmacy and a pharmacy benefit manager or third-party payer. A pharmacy
13 benefit manager or third-party payer may not enter into any contract that establishes payment for services or
14 medications based on an effective rate of reimbursement. A pharmacy benefit manager or third-party payer
15 found to be in violation of this section is subject to penalties, including but not limited to fines, revocation of
16 licensure, or other disciplinary actions.
17 (8) A pharmacy benefit manager may not:
18 (a) reimburse a network pharmacy an amount less than the contract price between the pharmacy
19 benefit manager and the insurer, third-party payor, or the pharmacy services management organization the
20 pharmacy benefit manager has contracted with; or
21 (b) require or coerce a patient to use a pharmacy that is owned by or affiliated with the pharmacy
22 benefit manager.
23 (9) A pharmacy benefit manager shall apply the same utilization review, fees, copayments or cost-
24 sharing, days allowance, and other conditions on a covered person when the covered person obtains a
25 prescription drug from a pharmacy that is included in the pharmacy benefit manager's pharmacy network,
26 including mail-order pharmacies and the pharmacy benefit manager’s owned, affiliated, or preferred
27 pharmacies.
- 8 - Authorized Print Version – HB 740

Amendment - 2nd Reading-yellow - Requested by: Marta Bertoglio - (H) Committee of the
Whole
- 2025
69th Legislature 2025 Drafter: Jameson Walker, HB0740.002.001
1 (10) If a covered person is using a mail-order pharmacy, the pharmacy benefit manager shall allow
2 for dispensing at local network pharmacies under the following circumstances to ensure patient access to
3 prescription drugs:
4 (a) if the prescription is delayed more than 1 day after the expected delivery date provided by the
5 mail-order pharmacy; or
6 (b) if the prescription drug arrives in an unusable condition as determined by the patient.
7 (11) A pharmacy benefit manager may not require the usage of mail order for a patient residing in
8 an area where the U.S. postal service does not provide service delivery to a physical address."
9
10 Section 7. Section 39-71-727, MCA, is amended to read:
11 "39-71-727. Payment for prescription drugs -- limitations. (1) For payment of prescription drugs,
12 an insurer is liable only for the purchase of generic-name drugs if the generic-name product is the therapeutic
13 equivalent of the brand-name drug prescribed by the physician, unless the generic-name drug is unavailable.
14 (2) If an injured worker prefers a brand-name drug, the worker may pay directly to the pharmacist
15 the difference in the reimbursement rate between the brand-name drug and the generic-name product, and the
16 pharmacist may bill the insurer only for the reimbursement rate of the generic-name drug.
17 (3) The pharmacist may bill only for the cost of the generic-name product on a signed itemized
18 billing, except if purchase of the brand-name drug is allowed as provided in subsection (1).
19 (4) When billing for a brand-name drug, the pharmacist shall certify that the generic-name drug
20 was unavailable.
21 (5) The department shall establish a schedule of fees for prescription drugs.
22 (6) Except as provided in subsection (8), a pharmacist may not dispense more than a 30-day
23 supply at any one time.
24 (7) For purposes of this section, the terms "brand name" and "generic name" have the meanings
25 provided in 37-7-502.
26 (8) An insurer may not require a worker receiving benefits under this chapter to obtain medications
27 from an out-of-state mail service pharmacy. However, an insurer may authorize up to a 90-day supply of
- 9 - Authorized Print Version – HB 740

Amendment - 2nd Reading-yellow - Requested by: Marta Bertoglio - (H) Committee of the
Whole
- 2025
69th Legislature 2025 Drafter: Jameson Walker, HB0740.002.001
1 medications from an in-state mail service pharmacy.
2 (9) The provisions of this section do not apply to an agreement between a preferred provider
3 organization and an insurer."
4
5 NEW SECTION. Section 7. Applicability. [This act] does not apply to the group health insurance
6 plan for state employees under Title 2, chapter 18, part 7.
7 - END -
- 10 - Authorized Print Version – HB 740

[DELETED:  D H- HIAPRAG30A2B4S5" P6n7()i8a9o0()r1s2f3()c4e5d6()u7r]
[DELETED:  D H- ()pr()c()rpolS0" D1d2()"3h4()"5c6e7p8()"920()"1s2()"3p4()"5b6p7()"]
[DELETED:  D H- hpp()"()t()ar()"a0i1()"2d3U4()"5()"6m7a8i0S1" M2m3()m4a5r6()m7w]
[DELETED:  D H- ()mS" Mdaptr0()I1b2()r3l4i5()e6t7p8()p9t0()I1m2()r3d4d5()p6s7()A]
[DELETED:  D H- ()p()p(()rt()(raM0a1t2()I3p4()f5i6a7()f8l9f1S2" A3t4r5()a6()a7()a]
[DELETED:  D H- ()a()as()ac()i()a()Ap0e1p2()O3m4()A5p6r7i8r9()A0o1e3S4" R5p6()p7()d]
[DELETED:  D H- rf()pb()mp()cm()A0()r1m2()e3s4o5()A6m7p8()A9t0e1m2()(3()o4a5()a6u7()e]
[DELETED:  D H- ap()eps()Aao()A0e1()E2a3b4m5f6l7()A8()r9b0p1()r2b3()A4s5p6i7p]
[DELETED:  D H- ()Ifp()im()i()Aa0S1" P2a3e4()I5t6p7()T8b9()W0w1()T2()E3s4()F5p6()A7f]
[DELETED:  D H- m()ToN Ap-]